Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Decitabine in Acute Myeloid Leukemia
NCT03844815Phase 1Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Nov 2019
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by University of Chicago. Primary endpoint: Dose Limiting Toxicity at 24 months. Started Nov 2019; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03844815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844815.